:format(webp)/cdn.mskdoctors.com/storage/2026/8/Tc7BZVSZxTAg9ngXUcrH97k20o8iK8T0.jpg)
ChondroFiller injection versus cartilage surgeryChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.ChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.
:format(webp)/cdn.mskdoctors.com/storage/2026/7/5pdsrZQlBz1P8ijm53n1ADWgRI8gx7rI.jpg)
ChondroFiller Injection Specialists in the UKAcross 19,000+ treated cases worldwide, ChondroFiller has a complication rate of 0.06%; 70–85% of patients with focal cartilage defects achieve meaningful symptom relief over 3–5 years through a collagen scaffold that recruits the patient's own repair cells.Across 19,000+ treated cases worldwide, ChondroFiller has a complication rate of 0.06%; 70–85% of patients with focal cartilage defects achieve meaningful symptom relief over 3–5 years through a collagen scaffold that recruits the patient's own repair cells.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/RkWBgYALriN0srVbg7pDPrpwetLHymaE.jpg)
How strong is ChondroFiller's clinical evidenceChondroFiller produces clinically meaningful functional improvement of approximately 30 IKDC points in knee patients, sustained at three-year follow-up, but published evidence extends no further, leaving long-term durability unproven.ChondroFiller produces clinically meaningful functional improvement of approximately 30 IKDC points in knee patients, sustained at three-year follow-up, but published evidence extends no further, leaving long-term durability unproven.
